Table 2. Annual Age-Stratified Numbers of PSA, Elevated PSA, and MRI Examinations Performed Within 180 Days After a PSA Test.
| Year | Age, y | Patients, No. (%) | Mean time between high PSA result and MRI, da | |||
|---|---|---|---|---|---|---|
| Receiving a PSA test | Undergoing MRI ≤180 d | With high PSA resulta | Undergoing MRI ≤180 d with high PSA resulta | |||
| 2011 | 40-54 | 39 049 (45.6) | 13 (0.03) | 419 (1.1) | 8 (1.9) | 81 (35.1) |
| 55-64 | 26 498 (31.0) | 30 (0.1) | 1178 (4.4) | 23 (2.0) | 71 (41.6) | |
| 65-74 | 13 859 (16.2) | 23 (0.2) | 1298 (9.4) | 13 (1.0) | 101 (42.8) | |
| 75-84 | 5720 (6.7) | 8 (0.1) | 1012 (17.7) | 5 (0.5) | 67 (54.0) | |
| ≥85 | 463 (0.5) | 0 | 102 (22.0) | 0 | NA | |
| 2012 | 40-54 | 33 563 (44.1) | 12 (0.04) | 366 (1.1) | 6 (1.6) | 91 (48.7) |
| 55-64 | 21 270 (27.9) | 31 (0.1) | 1002 (4.7) | 28 (2.8) | 93 (42.9) | |
| 65-74 | 14 623 (19.2) | 36 (0.2) | 1530 (10.5) | 27 (1.8) | 83 (51.5) | |
| 75-84 | 6214 (8.2) | 14 (0.2) | 1104 (17.8) | 9 (0.8) | 70 (32.1) | |
| ≥85 | 476 (0.6) | 1 (0.2) | 108 (22.7) | 0 | NA | |
| 2013 | 40-54 | 35 775 (40.2) | 13 (0.04) | 384 (1.1) | 9 (2.3) | 101 (54.4) |
| 55-64 | 24 708 (27.8) | 41 (0.2) | 1190 (4.8) | 34 (2.9) | 84 (41.4) | |
| 65-74 | 19 995 (22.5) | 57 (0.3) | 2046 (10.2) | 37 (1.8) | 91 (48.0) | |
| 75-84 | 6796 (7.6) | 8 (0.1) | 1112 (16.4) | 3 (0.3) | 97 (38.8) | |
| ≥85 | 1754 (2.0) | 1 (0.1) | 438 (25.0) | 1 (0.2) | 8 (NA) | |
| 2014 | 40-54 | 31 320 (40.3) | 15 (0.05) | 340 (1.1) | 8 (2.4) | 86 (39.6) |
| 55-64 | 21 550 (27.7) | 38 (0.2) | 1016 (4.7) | 26 (2.6) | 59 (40.7) | |
| 65-74 | 16 801 (21.6) | 45 (0.3) | 1816 (10.8) | 39 (2.1) | 74 (51.5) | |
| 75-84 | 6473 (8.3) | 21 (0.3) | 1161 (17.9) | 17 (1.5) | 62 (42.5) | |
| ≥85 | 1642 (2.1) | 2 (0.1) | 408 (24.8) | 2 (0.5) | 128 (7.1) | |
| 2015 | 40-54 | 38 620 (38.5) | 31 (0.1) | 434 (1.1) | 20 (4.6) | 75 (40.6) |
| 55-64 | 30 049 (29.9) | 82 (0.3) | 1588 (5.3) | 68 (4.3) | 77 (44.9) | |
| 65-74 | 21 064 (21.0) | 100 (0.5) | 2257 (10.7) | 76 (3.4) | 74 (45.3) | |
| 75-84 | 8204 (8.2) | 31 (0.4) | 1358 (16.6) | 23 (1.7) | 59 (36.3) | |
| ≥85 | 2414 (2.4) | 3 (0.1) | 554 (22.9) | 3 (0.5) | 52 (23.3) | |
| 2016 | 40-54 | 46 332 (35.4) | 53 (0.1) | 546 (1.2) | 39 (7.1) | 76 (42.6) |
| 55-64 | 40 950 (31.3) | 121 (0.3) | 2137 (5.2) | 98 (4.6) | 74 (44.4) | |
| 65-74 | 30 305 (23.2) | 181 (0.6) | 3288 (10.8) | 147 (4.5) | 76 (42.6) | |
| 75-84 | 10 695 (8.2) | 46 (0.4) | 1779 (16.6) | 34 (1.9) | 66 (45.5) | |
| ≥85 | 2442 (1.9) | 4 (0.2) | 618 (25.3) | 3 (0.5) | 72 (51.2) | |
| 2017 | 40-54 | 61 564 (26.2) | 66 (0.1) | 864 (1.4) | 48 (5.6) | 61 (39.9) |
| 55-64 | 59 443 (25.3) | 217 (0.4) | 3314 (5.6) | 164 (4.9) | 61 (42.6) | |
| 65-74 | 80 622 (34.3) | 458 (0.6) | 8809 (10.9) | 377 (4.3) | 60 (42.6) | |
| 75-84 | 27 439 (11.7) | 155 (0.6) | 4527 (16.5) | 121 (2.7) | 57 (44.9) | |
| ≥85 | 6117 (2.6) | 11 (0.2) | 1397 (22.8) | 8 (0.6) | 88 (35.9) | |
Abbreviations: MRI, magnetic resonance imaging; NA, not applicable; PSA, prostate-specific antigen.
a
High PSA results were considered levels 4 ng/mL or above.